Bruker Corporation (NASDAQ: BRKRP) Stock Competitors & Peer Comparison
See BRKRP's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BRKRP and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BRKRP | $439.40 | -0.27% | 8.8B | 238.80 | $1.84 | +0.34% |
| ABT | $116.64 | +2.19% | 201.8B | 22.39 | $5.21 | +2.13% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $329.45 | +0.53% | 126.3B | 24.59 | $13.39 | +1.06% |
| MDT | $93.35 | +1.14% | 119.5B | 16.88 | $5.53 | +3.06% |
| BSX | $50.37 | +2.03% | 74.9B | 16.25 | $3.10 | N/A |
| EW | $89.79 | -0.04% | 51.7B | 33.26 | $2.70 | N/A |
| DXCM | $92.34 | +2.35% | 34.8B | 36.21 | $2.55 | N/A |
| GEHC | $74.82 | +1.03% | 33.8B | 16.41 | $4.56 | +0.19% |
| RMD | $231.52 | +1.35% | 33.6B | 21.49 | $10.77 | +1.06% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
BRKRP vs ABT Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, ABT has a market cap of 201.8B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while ABT trades at $116.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas ABT's P/E ratio is 22.39. In terms of profitability, BRKRP's ROE is -0.03%, compared to ABT's ROE of +0.11%. Regarding short-term risk, BRKRP is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
BRKRP vs BSX-PA Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BRKRP's ROE is -0.03%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, BRKRP is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
BRKRP vs SYK Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, SYK has a market cap of 126.3B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while SYK trades at $329.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas SYK's P/E ratio is 24.59. In terms of profitability, BRKRP's ROE is -0.03%, compared to SYK's ROE of +0.16%. Regarding short-term risk, BRKRP is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check SYK's competition here
Medtronic plc (NYSE: MDT)
BRKRP vs MDT Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, MDT has a market cap of 119.5B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while MDT trades at $93.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas MDT's P/E ratio is 16.88. In terms of profitability, BRKRP's ROE is -0.03%, compared to MDT's ROE of +0.10%. Regarding short-term risk, BRKRP is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
BRKRP vs BSX Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, BSX has a market cap of 74.9B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while BSX trades at $50.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas BSX's P/E ratio is 16.25. In terms of profitability, BRKRP's ROE is -0.03%, compared to BSX's ROE of +0.15%. Regarding short-term risk, BRKRP is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
BRKRP vs EW Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while EW trades at $89.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas EW's P/E ratio is 33.26. In terms of profitability, BRKRP's ROE is -0.03%, compared to EW's ROE of +0.10%. Regarding short-term risk, BRKRP is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
BRKRP vs DXCM Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, DXCM has a market cap of 34.8B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while DXCM trades at $92.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas DXCM's P/E ratio is 36.21. In terms of profitability, BRKRP's ROE is -0.03%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, BRKRP is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
BRKRP vs GEHC Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, GEHC has a market cap of 33.8B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while GEHC trades at $74.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas GEHC's P/E ratio is 16.41. In terms of profitability, BRKRP's ROE is -0.03%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, BRKRP is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check GEHC's competition here
ResMed Inc. (NYSE: RMD)
BRKRP vs RMD Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, RMD has a market cap of 33.6B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while RMD trades at $231.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas RMD's P/E ratio is 21.49. In terms of profitability, BRKRP's ROE is -0.03%, compared to RMD's ROE of +0.24%. Regarding short-term risk, BRKRP is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
BRKRP vs PHG Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, PHG has a market cap of 26.8B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while PHG trades at $27.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas PHG's P/E ratio is 15.67. In terms of profitability, BRKRP's ROE is -0.03%, compared to PHG's ROE of +0.10%. Regarding short-term risk, BRKRP is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
BRKRP vs ZBH Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, ZBH has a market cap of 19.5B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while ZBH trades at $100.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas ZBH's P/E ratio is 11.91. In terms of profitability, BRKRP's ROE is -0.03%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BRKRP is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
BRKRP vs ABMD Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BRKRP's ROE is -0.03%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BRKRP is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
BRKRP vs PEN Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while PEN trades at $325.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas PEN's P/E ratio is 84.91. In terms of profitability, BRKRP's ROE is -0.03%, compared to PEN's ROE of +0.11%. Regarding short-term risk, BRKRP is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
BRKRP vs SWAV Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BRKRP's ROE is -0.03%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BRKRP is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
BRKRP vs SNN Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, SNN has a market cap of 12.3B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while SNN trades at $29.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas SNN's P/E ratio is 13.77. In terms of profitability, BRKRP's ROE is -0.03%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BRKRP is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check SNN's competition here
Globus Medical, Inc. (NYSE: GMED)
BRKRP vs GMED Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, GMED has a market cap of 11.7B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while GMED trades at $86.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas GMED's P/E ratio is 19.58. In terms of profitability, BRKRP's ROE is -0.03%, compared to GMED's ROE of +0.12%. Regarding short-term risk, BRKRP is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check GMED's competition here
Align Technology, Inc. (NASDAQ: ALGN)
BRKRP vs ALGN Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, ALGN has a market cap of 11.6B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while ALGN trades at $162.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas ALGN's P/E ratio is 14.82. In terms of profitability, BRKRP's ROE is -0.03%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, BRKRP is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check ALGN's competition here
Glaukos Corporation (NYSE: GKOS)
BRKRP vs GKOS Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, GKOS has a market cap of 10.9B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while GKOS trades at $184.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas GKOS's P/E ratio is -214.86. In terms of profitability, BRKRP's ROE is -0.03%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, BRKRP is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
BRKRP vs PODD Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, PODD has a market cap of 10.3B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while PODD trades at $148.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas PODD's P/E ratio is 25.24. In terms of profitability, BRKRP's ROE is -0.03%, compared to PODD's ROE of +0.27%. Regarding short-term risk, BRKRP is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
BRKRP vs BIO Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while BIO trades at $380.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas BIO's P/E ratio is 40.94. In terms of profitability, BRKRP's ROE is -0.03%, compared to BIO's ROE of +0.03%. Regarding short-term risk, BRKRP is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
BRKRP vs BIO-B Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, BIO-B has a market cap of 10B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while BIO-B trades at $365.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas BIO-B's P/E ratio is -64.28. In terms of profitability, BRKRP's ROE is -0.03%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, BRKRP is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check BIO-B's competition here
Masimo Corporation (NASDAQ: MASI)
BRKRP vs MASI Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas MASI's P/E ratio is 44.43. In terms of profitability, BRKRP's ROE is -0.03%, compared to MASI's ROE of +0.09%. Regarding short-term risk, BRKRP is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
BRKRP vs BRKR Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while BRKR trades at $59.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas BRKR's P/E ratio is 29.93. In terms of profitability, BRKRP's ROE is -0.03%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, BRKRP is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BRKR's competition here
Haemonetics Corporation (NYSE: HAE)
BRKRP vs HAE Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, HAE has a market cap of 4.9B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while HAE trades at $108.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas HAE's P/E ratio is 21.71. In terms of profitability, BRKRP's ROE is -0.03%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BRKRP is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
BRKRP vs NARI Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas NARI's P/E ratio is -59.24. In terms of profitability, BRKRP's ROE is -0.03%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BRKRP is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
BRKRP vs LIVN Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while LIVN trades at $78.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas LIVN's P/E ratio is 18.70. In terms of profitability, BRKRP's ROE is -0.03%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, BRKRP is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
BRKRP vs ITGR Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while ITGR trades at $125.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas ITGR's P/E ratio is 19.71. In terms of profitability, BRKRP's ROE is -0.03%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, BRKRP is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
BRKRP vs IRTC Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, IRTC has a market cap of 4.2B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while IRTC trades at $128.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas IRTC's P/E ratio is -200.81. In terms of profitability, BRKRP's ROE is -0.03%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, BRKRP is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
BRKRP vs AXNX Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BRKRP's ROE is -0.03%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BRKRP is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
BRKRP vs TMDX Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, TMDX has a market cap of 3.3B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while TMDX trades at $94.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas TMDX's P/E ratio is 48.06. In terms of profitability, BRKRP's ROE is -0.03%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, BRKRP is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
BRKRP vs AXGN Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, AXGN has a market cap of 2.7B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while AXGN trades at $50.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas AXGN's P/E ratio is 132.63. In terms of profitability, BRKRP's ROE is -0.03%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, BRKRP is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check AXGN's competition here
Butterfly Network, Inc. (NYSE: BFLY)
BRKRP vs BFLY Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, BFLY has a market cap of 2.5B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while BFLY trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas BFLY's P/E ratio is -39.79. In terms of profitability, BRKRP's ROE is -0.03%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, BRKRP is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BFLY's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
BRKRP vs UFPT Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, UFPT has a market cap of 2.4B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while UFPT trades at $309.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas UFPT's P/E ratio is 31.58. In terms of profitability, BRKRP's ROE is -0.03%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BRKRP is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
BRKRP vs ESTA Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while ESTA trades at $72.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas ESTA's P/E ratio is -57.67. In terms of profitability, BRKRP's ROE is -0.03%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, BRKRP is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
BRKRP vs NUVA Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BRKRP's ROE is -0.03%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BRKRP is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
BRKRP vs NVCR Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while NVCR trades at $17.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas NVCR's P/E ratio is -11.18. In terms of profitability, BRKRP's ROE is -0.03%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, BRKRP is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
BRKRP vs INSP Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while INSP trades at $62.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas INSP's P/E ratio is 27.51. In terms of profitability, BRKRP's ROE is -0.03%, compared to INSP's ROE of +0.18%. Regarding short-term risk, BRKRP is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check INSP's competition here
CONMED Corporation (NYSE: CNMD)
BRKRP vs CNMD Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while CNMD trades at $51.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas CNMD's P/E ratio is 11.29. In terms of profitability, BRKRP's ROE is -0.03%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, BRKRP is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check CNMD's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
BRKRP vs TNDM Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while TNDM trades at $22.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas TNDM's P/E ratio is -24.00. In terms of profitability, BRKRP's ROE is -0.03%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, BRKRP is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check TNDM's competition here
Enovis Corporation (NYSE: ENOV)
BRKRP vs ENOV Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while ENOV trades at $26.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas ENOV's P/E ratio is 7.46. In terms of profitability, BRKRP's ROE is -0.03%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, BRKRP is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check ENOV's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
BRKRP vs ATEC Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while ATEC trades at $9.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas ATEC's P/E ratio is -158.00. In terms of profitability, BRKRP's ROE is -0.03%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, BRKRP is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check ATEC's competition here
Artivion, Inc. (NYSE: AORT)
BRKRP vs AORT Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while AORT trades at $28.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas AORT's P/E ratio is 46.82. In terms of profitability, BRKRP's ROE is -0.03%, compared to AORT's ROE of -0.01%. Regarding short-term risk, BRKRP is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check AORT's competition here
Heska Corporation (NASDAQ: HSKA)
BRKRP vs HSKA Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BRKRP's ROE is -0.03%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BRKRP is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
BRKRP vs IART Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while IART trades at $16.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas IART's P/E ratio is 7.09. In terms of profitability, BRKRP's ROE is -0.03%, compared to IART's ROE of -0.01%. Regarding short-term risk, BRKRP is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check IART's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
BRKRP vs PRCT Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while PRCT trades at $21.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas PRCT's P/E ratio is -11.18. In terms of profitability, BRKRP's ROE is -0.03%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, BRKRP is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
BRKRP vs LMRI Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, LMRI has a market cap of 1.2B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while LMRI trades at $12.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas LMRI's P/E ratio is -24.16. In terms of profitability, BRKRP's ROE is -0.03%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, BRKRP is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check LMRI's competition here
Avanos Medical, Inc. (NYSE: AVNS)
BRKRP vs AVNS Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas AVNS's P/E ratio is 27.77. In terms of profitability, BRKRP's ROE is -0.03%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BRKRP is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check AVNS's competition here
IRadimed Corporation (NASDAQ: IRMD)
BRKRP vs IRMD Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while IRMD trades at $87.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas IRMD's P/E ratio is 44.15. In terms of profitability, BRKRP's ROE is -0.03%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, BRKRP is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check IRMD's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
BRKRP vs SILK Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas SILK's P/E ratio is -18.96. In terms of profitability, BRKRP's ROE is -0.03%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BRKRP is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
BRKRP vs FNA Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas FNA's P/E ratio is -19.83. In terms of profitability, BRKRP's ROE is -0.03%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BRKRP is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
BRKRP vs BVS Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, BVS has a market cap of 974.2M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while BVS trades at $14.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas BVS's P/E ratio is 18.92. In terms of profitability, BRKRP's ROE is -0.03%, compared to BVS's ROE of +0.28%. Regarding short-term risk, BRKRP is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
BRKRP vs CBLL Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, CBLL has a market cap of 922.4M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while CBLL trades at $24.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas CBLL's P/E ratio is -14.91. In terms of profitability, BRKRP's ROE is -0.03%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, BRKRP is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check CBLL's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
BRKRP vs SIBN Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, SIBN has a market cap of 885.2M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while SIBN trades at $19.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas SIBN's P/E ratio is -58.71. In terms of profitability, BRKRP's ROE is -0.03%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, BRKRP is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check SIBN's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
BRKRP vs AVR Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, AVR has a market cap of 873.1M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while AVR trades at $8.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas AVR's P/E ratio is -4.03. In terms of profitability, BRKRP's ROE is -0.03%, compared to AVR's ROE of -0.78%. Regarding short-term risk, BRKRP is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check AVR's competition here
InMode Ltd. (NASDAQ: INMD)
BRKRP vs INMD Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, INMD has a market cap of 865.7M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while INMD trades at $15.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas INMD's P/E ratio is 10.46. In terms of profitability, BRKRP's ROE is -0.03%, compared to INMD's ROE of +0.12%. Regarding short-term risk, BRKRP is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check INMD's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
BRKRP vs BBNX Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, BBNX has a market cap of 857.1M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while BBNX trades at $19.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas BBNX's P/E ratio is -12.62. In terms of profitability, BRKRP's ROE is -0.03%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, BRKRP is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BBNX's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
BRKRP vs CSII Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas CSII's P/E ratio is -20.83. In terms of profitability, BRKRP's ROE is -0.03%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BRKRP is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check CSII's competition here
Varex Imaging Corporation (NASDAQ: VREX)
BRKRP vs VREX Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, VREX has a market cap of 779.3M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while VREX trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas VREX's P/E ratio is 19.48. In terms of profitability, BRKRP's ROE is -0.03%, compared to VREX's ROE of +0.05%. Regarding short-term risk, BRKRP is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
BRKRP vs AHCO Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, AHCO has a market cap of 766M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while AHCO trades at $5.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas AHCO's P/E ratio is 11.49. In terms of profitability, BRKRP's ROE is -0.03%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, BRKRP is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check AHCO's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
BRKRP vs SSII Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, SSII has a market cap of 717.5M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while SSII trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas SSII's P/E ratio is -69.92. In terms of profitability, BRKRP's ROE is -0.03%, compared to SSII's ROE of -0.27%. Regarding short-term risk, BRKRP is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check SSII's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
BRKRP vs KIDS Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, KIDS has a market cap of 658.8M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while KIDS trades at $25.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas KIDS's P/E ratio is -21.74. In terms of profitability, BRKRP's ROE is -0.03%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, BRKRP is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check KIDS's competition here
Surmodics, Inc. (NASDAQ: SRDX)
BRKRP vs SRDX Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BRKRP's ROE is -0.03%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, BRKRP is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
BRKRP vs CTKB Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, CTKB has a market cap of 601.8M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while CTKB trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas CTKB's P/E ratio is -24.69. In terms of profitability, BRKRP's ROE is -0.03%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, BRKRP is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check CTKB's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
BRKRP vs DCTH Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, DCTH has a market cap of 591.7M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while DCTH trades at $17.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas DCTH's P/E ratio is 1714.00. In terms of profitability, BRKRP's ROE is -0.03%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, BRKRP is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check DCTH's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
BRKRP vs APEN Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas APEN's P/E ratio is -9.43. In terms of profitability, BRKRP's ROE is -0.03%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BRKRP is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check APEN's competition here
Cerus Corporation (NASDAQ: CERS)
BRKRP vs CERS Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, CERS has a market cap of 562.3M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while CERS trades at $2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas CERS's P/E ratio is -55.69. In terms of profitability, BRKRP's ROE is -0.03%, compared to CERS's ROE of -0.10%. Regarding short-term risk, BRKRP is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check CERS's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
BRKRP vs TCMD Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, TCMD has a market cap of 537.3M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while TCMD trades at $23.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas TCMD's P/E ratio is 22.06. In terms of profitability, BRKRP's ROE is -0.03%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, BRKRP is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check TCMD's competition here
ZimVie Inc. (NASDAQ: ZIMV)
BRKRP vs ZIMV Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BRKRP's ROE is -0.03%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, BRKRP is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check ZIMV's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
BRKRP vs NPCE Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, NPCE has a market cap of 478.3M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while NPCE trades at $14.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas NPCE's P/E ratio is -24.61. In terms of profitability, BRKRP's ROE is -0.03%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, BRKRP is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
BRKRP vs CLPT Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, CLPT has a market cap of 455.5M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while CLPT trades at $15.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas CLPT's P/E ratio is -12.87. In terms of profitability, BRKRP's ROE is -0.03%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, BRKRP is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check CLPT's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
BRKRP vs SGHT Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, SGHT has a market cap of 449.4M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while SGHT trades at $8.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas SGHT's P/E ratio is -14.75. In terms of profitability, BRKRP's ROE is -0.03%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, BRKRP is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check SGHT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
BRKRP vs CARL Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, CARL has a market cap of 448.6M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while CARL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas CARL's P/E ratio is -11.54. In terms of profitability, BRKRP's ROE is -0.03%, compared to CARL's ROE of -0.38%. Regarding short-term risk, BRKRP is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check CARL's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
BRKRP vs PACB Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, PACB has a market cap of 427.1M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while PACB trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas PACB's P/E ratio is -3.35. In terms of profitability, BRKRP's ROE is -0.03%, compared to PACB's ROE of -49.62%. Regarding short-term risk, BRKRP is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check PACB's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
BRKRP vs SENS Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, SENS has a market cap of 405.8M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while SENS trades at $9.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas SENS's P/E ratio is -4.35. In terms of profitability, BRKRP's ROE is -0.03%, compared to SENS's ROE of -1.66%. Regarding short-term risk, BRKRP is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
BRKRP vs OFIX Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, OFIX has a market cap of 404.6M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while OFIX trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas OFIX's P/E ratio is -13.08. In terms of profitability, BRKRP's ROE is -0.03%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, BRKRP is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check OFIX's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
BRKRP vs CATX Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, CATX has a market cap of 367.2M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while CATX trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas CATX's P/E ratio is -2.42. In terms of profitability, BRKRP's ROE is -0.03%, compared to CATX's ROE of -0.42%. Regarding short-term risk, BRKRP is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check CATX's competition here
Electromed, Inc. (AMEX: ELMD)
BRKRP vs ELMD Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, ELMD has a market cap of 327.5M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while ELMD trades at $39.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas ELMD's P/E ratio is 33.80. In terms of profitability, BRKRP's ROE is -0.03%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, BRKRP is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check ELMD's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
BRKRP vs TLSI Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, TLSI has a market cap of 324.5M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while TLSI trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas TLSI's P/E ratio is -3.14. In terms of profitability, BRKRP's ROE is -0.03%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, BRKRP is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check TLSI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
BRKRP vs SMLR Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BRKRP's ROE is -0.03%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, BRKRP is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check SMLR's competition here
CapsoVision, Inc. (NASDAQ: CV)
BRKRP vs CV Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, CV has a market cap of 300.8M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while CV trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas CV's P/E ratio is -2.41. In terms of profitability, BRKRP's ROE is -0.03%, compared to CV's ROE of -1.78%. Regarding short-term risk, BRKRP is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check CV's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
BRKRP vs TMCI Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, TMCI has a market cap of 281.5M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while TMCI trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas TMCI's P/E ratio is -4.62. In terms of profitability, BRKRP's ROE is -0.03%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, BRKRP is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check TMCI's competition here
RxSight, Inc. (NASDAQ: RXST)
BRKRP vs RXST Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, RXST has a market cap of 258.7M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while RXST trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas RXST's P/E ratio is -5.53. In terms of profitability, BRKRP's ROE is -0.03%, compared to RXST's ROE of -0.17%. Regarding short-term risk, BRKRP is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check RXST's competition here
Avita Medical Inc. (NASDAQ: RCEL)
BRKRP vs RCEL Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, RCEL has a market cap of 249.9M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while RCEL trades at $10.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas RCEL's P/E ratio is -6.99. In terms of profitability, BRKRP's ROE is -0.03%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, BRKRP is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check RCEL's competition here
Profound Medical Corp. (NASDAQ: PROF)
BRKRP vs PROF Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, PROF has a market cap of 246.7M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while PROF trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas PROF's P/E ratio is -6.93. In terms of profitability, BRKRP's ROE is -0.03%, compared to PROF's ROE of -0.56%. Regarding short-term risk, BRKRP is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check PROF's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
BRKRP vs MGRM Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas MGRM's P/E ratio is -12.00. In terms of profitability, BRKRP's ROE is -0.03%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, BRKRP is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check MGRM's competition here
Nevro Corp. (NYSE: NVRO)
BRKRP vs NVRO Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BRKRP's ROE is -0.03%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BRKRP is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
BRKRP vs STIM Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, STIM has a market cap of 208.8M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while STIM trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas STIM's P/E ratio is -6.82. In terms of profitability, BRKRP's ROE is -0.03%, compared to STIM's ROE of -1.51%. Regarding short-term risk, BRKRP is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
BRKRP vs BSGM Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BRKRP's ROE is -0.03%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, BRKRP is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
BRKRP vs LUCD Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, LUCD has a market cap of 184M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while LUCD trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas LUCD's P/E ratio is -2.61. In terms of profitability, BRKRP's ROE is -0.03%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, BRKRP is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
BRKRP vs MDGS Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BRKRP's ROE is -0.03%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BRKRP is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check MDGS's competition here
Quantum-Si incorporated (NASDAQ: QSI)
BRKRP vs QSI Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, QSI has a market cap of 165.2M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while QSI trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas QSI's P/E ratio is -1.82. In terms of profitability, BRKRP's ROE is -0.03%, compared to QSI's ROE of -0.47%. Regarding short-term risk, BRKRP is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check QSI's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
BRKRP vs QIPT Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BRKRP's ROE is -0.03%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, BRKRP is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
BRKRP vs FOCL Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, FOCL has a market cap of 154.8M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while FOCL trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas FOCL's P/E ratio is -3.99. In terms of profitability, BRKRP's ROE is -0.03%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, BRKRP is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check FOCL's competition here
Inogen, Inc. (NASDAQ: INGN)
BRKRP vs INGN Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, INGN has a market cap of 151.9M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while INGN trades at $5.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas INGN's P/E ratio is -6.16. In terms of profitability, BRKRP's ROE is -0.03%, compared to INGN's ROE of -0.13%. Regarding short-term risk, BRKRP is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
BRKRP vs QTRX Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, QTRX has a market cap of 140.8M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while QTRX trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas QTRX's P/E ratio is -1.18. In terms of profitability, BRKRP's ROE is -0.03%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, BRKRP is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check QTRX's competition here
LENSAR Inc (NASDAQ: LNSR)
BRKRP vs LNSR Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, LNSR has a market cap of 106.6M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while LNSR trades at $8.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas LNSR's P/E ratio is 8.86. In terms of profitability, BRKRP's ROE is -0.03%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, BRKRP is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check LNSR's competition here
iCAD, Inc. (NASDAQ: ICAD)
BRKRP vs ICAD Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas ICAD's P/E ratio is -20.37. In terms of profitability, BRKRP's ROE is -0.03%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, BRKRP is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for BRKRP.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
BRKRP vs HJLI Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas HJLI's P/E ratio is N/A. In terms of profitability, BRKRP's ROE is -0.03%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, BRKRP is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check HJLI's competition here
Pulmonx Corporation (NASDAQ: LUNG)
BRKRP vs LUNG Comparison August 2026
Bruker Corporation (NASDAQ: BRKRP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BRKRP stands at 8.8B. In comparison, LUNG has a market cap of 95.5M. Regarding current trading prices, BRKRP is priced at $439.40 on the NASDAQ, while LUNG trades at $2.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BRKRP currently has a P/E ratio of 238.80, whereas LUNG's P/E ratio is -1.95. In terms of profitability, BRKRP's ROE is -0.03%, compared to LUNG's ROE of -0.97%. Regarding short-term risk, BRKRP is less volatile compared to LUNG. This indicates lower risk in terms of short-term price fluctuations for BRKRP.Check LUNG's competition here